Good afternoon :)
Aarti Drugs Ltd

Aarti Drugs Ltd

AARTIDRUGS Share Price

NSE
₹446.750.36% (+1.60)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max
SIP

With a market cap of ₹4,077 cr, stock is ranked 936

Stock is 2.34x as volatile as Nifty

AARTIDRUGS Stock Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Good

The stock is underpriced and is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

With a market cap of ₹4,077 cr, stock is ranked 936

Stock is 2.34x as volatile as Nifty

AARTIDRUGS Performance & Key Metrics

AARTIDRUGS Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
17.822.630.45%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
44.365.940.49%

AARTIDRUGS Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 
100%
Analysts have suggested that investors can buy this stock

from 1 analyst

Price Upside

Earnings Growth

Rev. Growth

See Detailed Forecast

AARTIDRUGS Company Profile

Aarti Drugs Limited is a pharmaceutical company offering active pharmaceutical ingredients (APIs) in a range of therapeutic categories, such as anti-inflammatory, cardioprotectant, antifungals, antibiotic, antidiabetic, sedative and vitamins.

Investor Presentation

View older View older 

Nov 3, 2026

PDF
View Older Presentations

AARTIDRUGS Similar Stocks (Peers)

Compare with peers Compare with peers 

AARTIDRUGS Similar Stocks (Peers)

Compare with peers Compare with peers 
PE Ratio
35.76
35.76
1Y Return
10.33%
10.33%
Buy Reco %
93.55
93.55
PE Ratio
82.09
82.09
1Y Return
33.67%
33.67%
Buy Reco %
85.19
85.19
LAURUSLABS
PE Ratio
142.25
142.25
1Y Return
138.82%
138.82%
Buy Reco %
61.54
61.54
PE Ratio
21.77
21.77
1Y Return
27.89%
27.89%
Buy Reco %
57.69
57.69
PE Ratio
27.28
27.28
1Y Return
13.92%
13.92%
Buy Reco %
67.74
67.74
Compare with Peers

AARTIDRUGS Sentiment Analysis

AARTIDRUGS Sentiment Analysis

New
Crisp summary & key insights to decode earnings calls instantly

AARTIDRUGS Stock Summary · August 2026

Management described a strong start to FY27, with growth led mainly by pricing even as domestic and local volumes still rose about 3.5%. Standalone revenue increased 20% year on year, while EBITDA and profit before tax also improved, helped by margin expansion; reported PAT, however, fell from the prior year because that quarter had included a principal tax refund. The quarter was marked by fully stable operations, with no production disruptions or material shortages, and by better API realizations as industry pricing firmed and supply tightened. Management emphasised manufacturing reliability, disciplined inventory and procurement, and the growing importance of regulated-market approvals, which they said should support pricing, volumes, and margins over time. Sayakha was highlighted as a key growth and integration driver, with utilization above 60% and specialty chemicals sales up 149% to about INR82 crore. At the same time, management noted ongoing pressure from raw materials, freight, and a one-time write-off. They said 14% EBITDA margin is already achievable, 15% should become easier as utilization rises, and volume growth of 10% to 15% is expected over the next two years.

AARTIDRUGS Stock Growth Drivers
AARTIDRUGS Stock Growth Drivers
11
  • Improved pricing and realization environment

    The company benefited from a tighter API market and higher industry-wide pricing, which lifted realizations

  • Healthy demand and stronger customer positioning

    Demand remained solid across APIs, specialty chemicals, and formulations, supported by traction in both domestic

AARTIDRUGS Stock Challenges
AARTIDRUGS Stock Challenges
4
  • Supply Chain and Cost Volatility

    The company continues to face a difficult external operating environment marked by geopolitical uncertainty, higher

  • Delayed Market Access for Metformin US Supply

    Commercial shipments of metformin to the US remain blocked until the new 500+ tons per

AARTIDRUGS Forecast

AARTIDRUGS Forecasts

Price

Revenue

Earnings

AARTIDRUGS

AARTIDRUGS

Income

Balance Sheet

Cash Flow

AARTIDRUGS Income Statement

AARTIDRUGS Income Statement

Loading...

Quarterjun 2024sep 2024dec 2024mar 2025jun 2025sep 2025dec 2025mar 2026jun 2026sep 2026
Total Revenue556.45599.81568.50678.63590.82652.88602.94721.06703.59828.79
Operating & Other expensessubtract490.38531.28494.87583.43516.43568.51546.68624.50606.67690.88
Depreciation/Amortizationsubtract13.3813.7213.8014.8814.7216.2617.9518.0418.4619.00
Interest & Other Itemssubtract8.718.939.079.168.567.709.298.169.229.63
Taxes & Other Itemssubtract10.7410.8713.718.30-2.8015.13-11.5215.1719.0726.34
EPS3.623.834.066.885.914.954.446.055.499.07

AARTIDRUGS Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2027FY 2027

Annual Report Pending

Investor Presentation

Nov 3PDF
Aug 1PDF
FY 2026FY 2026

Annual report

PDF

Investor Presentation

May 16PDF
Feb 3PDF
Nov 7PDF
Jul 19PDF
FY 2025FY 2025

Annual report

PDF

Investor Presentation

May 6PDF
Jan 29PDF
Sep 20PDF
FY 2024FY 2024

Annual report

PDF

Investor Presentation

Jul 21PDF
FY 2023FY 2023

Annual report

PDF
FY 2022FY 2022

Annual report

PDF
FY 2021FY 2021

Annual report

PDF
FY 2020FY 2020

Annual report

PDF
FY 2019FY 2019

Annual report

PDF
FY 2018FY 2018

Annual report

PDF
FY 2017FY 2017

Annual report

PDF
 

AARTIDRUGS Stock Peers

AARTIDRUGS Past Performance & Peer Comparison

AARTIDRUGS Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Aarti Drugs Ltd20.922.630.45%
Sun Pharmaceutical Industries Limited35.765.320.86%
Torrent Pharmaceuticals Ltd82.0910.270.71%
Laurus Labs Ltd142.2523.280.09%
ScreenerCompare valuation on Screener

AARTIDRUGS Stock Price Comparison

Compare AARTIDRUGS with any stock or ETF
Compare AARTIDRUGS with any stock or ETF
AARTIDRUGS
Loading...

AARTIDRUGS Holdings

AARTIDRUGS Shareholdings

AARTIDRUGS Promoter Holdings Trend

AARTIDRUGS Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

AARTIDRUGS Institutional Holdings Trend

AARTIDRUGS Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

AARTIDRUGS Shareholding Pattern

AARTIDRUGS Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding54.07%9.97%0.27%2.26%33.43%

Dec 2025

Mar 2026

Jun 2026

Sep 2026

AARTIDRUGS Shareholding History

AARTIDRUGS Shareholding History

JunSepDec '25MarJunSep2.26%2.69%2.15%1.58%1.52%2.26%

Mutual Funds Invested in AARTIDRUGS

Mutual Funds Invested in AARTIDRUGS

No mutual funds holding trends are available

Top 5 Mutual Funds holding Aarti Drugs Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
0.0005%0.10%0.01%103/146 (-5)
0.0001%0.01%0.00%901/1013 (-8)
0.0000%0.98%0.06%0/36 (0)

Compare 3-month MF holding change on Screener

AARTIDRUGS Insider Trades & Bulk Stock Deals

AARTIDRUGS Insider Trades & Bulk Stock Deals

Loading...

smallcases containing AARTIDRUGS stock

smallcases containing AARTIDRUGS stock

Looks like this stock is not in any smallcase yet.

AARTIDRUGS Events

AARTIDRUGS Events

AARTIDRUGS Dividend Trend

No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year

AARTIDRUGS has increased or maintained dividend levels over the last 5 years

Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.45%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹4.48 every year

Dividends

Corp. Actions

Announcements

Legal Orders

AARTIDRUGS Dividend Trend

No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year

AARTIDRUGS has increased or maintained dividend levels over the last 5 years

Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.45%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹4.48 every year

AARTIDRUGS Upcoming Dividends

AARTIDRUGS Upcoming Dividends

No upcoming dividends are available

AARTIDRUGS Past Dividends

AARTIDRUGS Past Dividends

Cash Dividend

Ex DateEx DateFeb 9, 2026

Interim
Interim | Div/Share: ₹2.00

Dividend/Share

₹2.00

Ex DateEx Date

Feb 9, 2026

Cash Dividend

Ex DateEx DateFeb 4, 2025

Interim
Interim | Div/Share: ₹1.00

Dividend/Share

₹1.00

Ex DateEx Date

Feb 4, 2025

Cash Dividend

Ex DateEx DateFeb 6, 2024

Interim
Interim | Div/Share: ₹1.00

Dividend/Share

₹1.00

Ex DateEx Date

Feb 6, 2024

Cash Dividend

Ex DateEx DateFeb 8, 2023

Interim
Interim | Div/Share: ₹1.00

Dividend/Share

₹1.00

Ex DateEx Date

Feb 8, 2023

Cash Dividend

Ex DateEx DateFeb 9, 2022

Interim
Interim | Div/Share: ₹1.00

Dividend/Share

₹1.00

Ex DateEx Date

Feb 9, 2022

AARTIDRUGS Stock News & Opinions

AARTIDRUGS Stock News & Opinions

Earnings
Earnings
Aarti Drugs Ltd consolidated sales up 17.57% on year in Q3FY2026, net profit soared by 65.11%

Aarti Drugs Ltd share price gained 2.60% to Rs 465.6 after the company's net profit saw a strong growth of 65.11% to Rs 82.77 crore, while revenue from operations increased 17.57% to Rs 826.24 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.73 lakh crore, rising 5.41%. It has improved by 1.84% over last one week and gained upto 1.37% in last one month while the market capitalization of Aarti Drugs Ltd has marginally improved by 4% and 13.30% in the same period respectively. Profit before tax (PBT) of Aarti Drugs Ltd stood at Rs 109.28 crore in Q3 FY26, jumping 80.90% year-on-year, and surging by 57.83% quarter-on-quarter. EBITDA came in at Rs 133 crore, rallying 57.75% YoY and expanding by 36.37% sequentially. Total expenses increased by 13.94% to Rs 709.88 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 477.33 crore, posting a minor increase of 1.70% YoY, while employee benefits expense was at Rs 37.13 crore, ticking higher by 1.70% YoY. For the TTM ended FY26, revenue from operations inched higher 7.47% to Rs 2565.31 crore, while net profit rose by 15.97% to Rs 194.94 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 28089% to Rs 306.8 crore, and PBT softened 0.41% to Rs 210.9 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 253.54 crore in FY26, as against Rs 244.58 crore in FY25. Aarti Drugs Ltd retreated by 7.39% in last one year, outperforming the benchmark BSE Sensex which has slipped by 8.41% during the same period.

3 days agoCapital Market - Live
Corporate
Corporate
Aarti Drugs to convene a board meeting November 3 to review financial results

Aarti Drugs Limited will hold a board meeting on Tuesday, November 3, 2026, to consider and approve audited financial results for the quarter and half year ended September 30, 2026, according to a regulatory filing. The trading window for the company will remain closed for 48 hours after the declaration of the financial results, following an earlier intimation dated September 29, 2026.

1 week agoCapital Market - Live
Corporate
Corporate
Aarti Drugs reported securities dematerialization processing confirmation from MUFG Intime India

Aarti Drugs Limited informed the BSE and National Stock Exchange that MUFG Intime India Private Limited, formerly Link Intime India Private Limited, confirmed the receipt and processing of securities for dematerialization during the quarter ended September 30, 2026, in accordance with Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018.

1 month agoCapital Market - Live
Corporate
Corporate
Aarti Drugs will halt trading ahead of financial results declaration in late September

Aarti Drugs Limited will close its trading window from October 1, 2026, until 48 hours after the declaration of financial results for the quarter and half year ended September 30, 2026, as per SEBI (Prohibition of Insider Trading) Regulations, 2015, the company said in a filing to the BSE Limited and National Stock Exchange of India Limited.

1 month agoCapital Market - Live
Corporate
Corporate
Aarti Drugs appoints Adhish Patil as Managing Director, effective October 1, 2026

Aarti Drugs Limited announced several changes to its management at its 41st Annual General Meeting on September 26, 2026. Uday Moreshwar Patil retired as Whole Time Director, and Nilesh Bhalchandra Patil was appointed as Director and Whole Time Director, effective September 26, 2026. Additionally, Adhish Prakash Patil will assume the role of Managing Director, effective October 1, 2026, while Harshit Manilal Savla, Harit Pragji Shah, Hasmukh Bhavanji Dedhia, Ajit Eledath Venugopalan, and Sandeep Madhusudan Joshi were re-appointed as Joint Managing Director, Whole Time Director, and Independent Directors, respectively, for further terms.

1 month agoCapital Market - Live
Corporate
Corporate
Aarti Drugs to convene board meeting August 27th to approve a stock option plan

Aarti Drugs Limited will hold a board meeting on Thursday, August 27, 2026, to consider and approve the “Aarti Drugs Limited – Performance Stock Option Plan 2026,” and the trading window for the company will be closed from August 25, 2026, until August 29, 2026, in accordance with SEBI regulations.

2 months agoCapital Market - Live
Corporate
Corporate
Aarti Drugs to convene board meeting August 27th to approve a stock option plan

Aarti Drugs Limited will hold a board meeting on Thursday, August 27, 2026, to consider and approve the “Aarti Drugs Limited – Performance Stock Option Plan 2026,” and the trading window for the company will be closed from August 25, 2026, until August 29, 2026, in accordance with SEBI regulations.

2 months agoCapital Market - Live
Corporate
Corporate
Aarti Drugs’ revenue increased 19% to Rs 703.6 crore for the quarter ended June 30, 2026

Aarti Drugs Limited (NSE: AARTIDRUGS; BSE:524348) announced consolidated financial results for the quarter ended June 30, 2026, reporting total revenue of Rs 703.6 crore, a 19% year-over-year increase compared to Rs 590.8 crore in the prior year’s corresponding quarter. The company’s EBITDA rose to Rs 96.9 crore, a 30% increase year-over-year, with an EBITDA margin expansion of 120 basis points to 13.8%, while profit after tax stood at Rs 50.1 crore. Aarti Drugs’ Chief Financial Officer and Chief Operating Officer, Adhish Patil, noted a recovery in pricing environments and emphasized ongoing investments in capacity enhancement and backward integration, including expansion of oral solid dosage capabilities in Baddi, Himachal Pradesh.

3 months agoCapital Market - Live
Corporate
Corporate
Aarti Drugs names Rashesh Gogri Chairman, Adhish Patil Managing Director, effective October 1

Aarti Drugs Limited announced leadership changes effective October 1, 2026, with Shri Rashesh C. Gogri being elevated to Chairman in addition to his role as Managing Director, and Shri Adhish P. Patil appointed as Managing Director, subject to shareholder approval. Current Chairman, Managing Director and CEO Shri Prakash M. Patil will step down from his executive responsibilities at the close of business hours on September 30, 2026, and will continue to provide guidance and support during the transition. The changes, recommended by the Nomination and Remuneration Committee, are aimed at strengthening governance and ensuring long-term strategic growth for the Mumbai-based API pharmaceutical company, which is part of the $6 billion Aarti Group of Industries.

3 months agoCapital Market - Live
Earnings
Earnings
Aarti Drugs Ltd consolidated sales down 2.43% on year in Q2FY2026

Aarti Drugs Ltd share price gained 2.64% to Rs 423.5. The Company's net profit softened by 9.28% to Rs 50.13 crore, while revenue from operations eased by 2.43% to Rs 702.78 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 23.86 lakh crore, gaining 5.88%. It has improved by 2.79% over last one week and rallied by 15.59% in last one month while the market capitalization of Aarti Drugs Ltd has marginally improved by 4.66% and 12.92% in the same period respectively. Profit before tax (PBT) of Aarti Drugs Ltd stood at Rs 69.24 crore in Q2 FY26, expanding by 35.47% year-on-year, and slipping 1.59% quarter-on-quarter. EBITDA came in at Rs 97 crore, surging by 32.02% YoY and rising 2.47% sequentially. Total expenses slightly declined by 3.03% to Rs 623.04 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 469.35 crore, posting a minor increase of 9.87% YoY, while employee benefits expense was at Rs 36.51 crore, surging 13.10% YoY. For the TTM ended FY26, revenue from operations declined slightly by 5.60% to Rs 2387.03 crore, while net profit slipped by 2.03% to Rs 168.1 crore, compared to previous TTM. EBITDA jumped by 31576% to Rs 270.7 crore, and PBT contracted 10.08% to Rs 211.77 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 244.58 crore in FY26, as against Rs 358.92 crore in FY25. Aarti Drugs Ltd crashed 21.03% in last one year, underperforming the benchmark BSE Sensex which has slipped by 4.36% during the same period.

3 months agoCapital Market - Live

Frequently asked questions

  1. The share price of AARTIDRUGS as on 6th November 2026 is ₹446.75. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. The past returns of Aarti Drugs Ltd (AARTIDRUGS) share are
    • Past 1 week: 1.05%
    • Past 1 month: 6.81%
    • Past 3 months: 8.74%
    • Past 6 months: 11.56%
    • Past 1 year: -8.62%
    • Past 3 years: -5.65%
    • Past 5 years: -20.96%

  3. The current dividend yield of Aarti Drugs Ltd (AARTIDRUGS) is 0.45.

  4. Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Aarti Drugs Ltd (AARTIDRUGS) is ₹4077.49 Cr as of 6th November 2026.

  5. The 52-week high of Aarti Drugs Ltd (AARTIDRUGS) is ₹534 and the 52-week low is ₹318.95.

  6. The P/E (price-to-earnings) ratio of Aarti Drugs Ltd (AARTIDRUGS) is 20.92. The P/B (price-to-book) ratio is 2.63.

  7. Aarti Drugs Ltd (AARTIDRUGS) belongs to the Health Care sector & Pharmaceuticals sub-sector.

  8. You can directly buy Aarti Drugs Ltd (AARTIDRUGS) shares on Tickertape. Simply sign up, connect your demat account and place your order.